Search the Newsreel

Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale

Precigen, Inc. has filed a Form 144 notice for the sale of 32,739 common shares with an aggregate value of $224,589.54 through Fidelity Brokerage Services LLC on NASDAQ. These shares were originally acquired through restricted stock vesting as compensation on three different dates between …

Precigen (PGEN) Stock Rallies As PAPZIMEOS Delivers First Clean Profit

Precigen (PGEN) stock rallied 5.5% after the company reported its first profitable quarter, driven by strong sales of its new therapy, PAPZIMEOS, for recurrent respiratory papillomatosis. Q2 revenue reached US$55 million, with PAPZIMEOS contributing US$53.1 million, resulting in a net income of US$20.1 million. …

Germantown biopharma Precigen turns first quarterly profit after key drug scores FDA approval

Germantown-based biopharma company Precigen Inc. has reported its first quarterly profit. This achievement comes a year after its immunotherapy drug received FDA approval, with sales of the drug being the main driver of the profit.

Cigna Healthcare Names Luke Cirkovic General Manager for Northern California Market

Cigna Healthcare has appointed Luke Cirkovic as the new general manager for its Northern California market, effective August 10, 2026. Cirkovic will focus on driving customer and earnings growth for employers with up to 2,999 employees and strengthening Cigna Healthcare's presence in the community. …

The CEO Who Built Modern Cigna

This article details David Cordani's 17-year tenure as Cigna CEO, during which he transformed the company into a $275 billion healthcare giant. The author highlights Cordani's strategic maneuvers, including the acquisition of Express Scripts, and discusses the mounting legal scrutiny and controversies, such as …

PRECIGEN, INC. 2026: Revenue $54.98M, EPS $0.05— 10-Q Summary

PRECIGEN, INC. (PGEN) reported strong results for the quarter ending 2026, with revenue reaching $54.98 million and diluted EPS at $0.05, significantly improving from the prior year. This growth was primarily driven by the successful commercial launch of Papzimeos, following its FDA approval in …

Precigen Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

HC Wainwright & Co. has reiterated its Buy rating for Precigen, maintaining a price target of $14.00 per share. This indicates continued analyst confidence in the company's stock performance.

Precigen (NASDAQ:PGEN) Announces Earnings Results

Precigen (PGEN) Stock Rises on Q2 2026 Earnings

Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary

Precigen, Inc. has released its earnings summary for the quarter that concluded on June 30. The article is from Refinitiv and is hosted on TradingView, which also offers access to news from Reuters and other sources.

Precigen GAAP EPS of $0.05 beats by $0.06, revenue of $54.98M beats by $27.15M

* Precigen press release [https://seekingalpha.com/pr/20606749-precigen-reports-second-quarter-2026-financial-results-highlighted-by-accelerating-papzimeos] (PGEN [https://seekingalpha.com/symbol/PGEN]): Q2 GAAP EPS of $0.05 beats by $0.06. * Revenue of $54.98M beats by $27.15M. MORE ON PRECIGEN * Precigen: Entering The Oncology 'Sweet Spot' [https://seekingalpha.com/article/4918147-precigen-entering-the-oncology-sweet-spot] * Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global …

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

Precigen announced strong second-quarter 2026 financial results, driven by accelerated revenue growth from its PAPZIMEOS treatment, which generated $53.1 million. The company achieved quarterly profitability and expects to reach cash flow break-even by the end of 2026, supported by broad U.S. adoption, seven-year market …

Cigna Group (CI) Faces A Valuation Test As Earnings Strength Meets PBM Concerns

Cigna Group (CI) is facing a valuation test as its recent earnings strength and shareholder returns are balanced against PBM (Pharmacy Benefit Manager) concerns and a recent downgrade. Despite these headwinds, the company is seen as undervalued by Simply Wall St's narrative, with a …

Jefferies downgrades Cigna to Hold on mounting 2027 earnings headwinds

Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336. The brokerage said consensus earnings expectations for 2027 remain too …

Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates

Precigen, Inc. (PGEN) reported Q2 earnings of $0.05 per share, significantly surpassing the Zacks Consensus Estimate of a $0.02 loss, and revenues of $54.98 million, exceeding expectations by 97.62%. The company has outperformed the S&P 500 this year with a 58.1% gain, and currently …

Precigen earnings set to test gene therapy growth trajectory

Precigen Inc. is set to announce its second-quarter results, with investors keenly watching for continued revenue growth from its PAPZIMEOS gene therapy launch and progress towards profitability. Analysts anticipate a loss of $0.01 per share on $27.83 million in revenue, driven by strong market …

CI Downgraded by Jefferies -- Price Target Lowered to $307

Jefferies has downgraded Cigna Group (CI) to a "Hold" rating, lowering its price target to $307 from $336 due to a cautious outlook on the company's performance. Despite a seemingly undervalued P/E ratio and strong profitability and growth ranks, significant insider selling of $59.4 …

Gráfico Cia Energetica Minas Gerais Cemig (CMIG4)

This page displays the live stock chart for Cia Energetica Minas Gerais Cemig (CMIG4) on the BOV exchange. It provides current stock data, including the latest price, daily change, and closing time. The page also offers various tools and information related to CMIG4, such …

Cigna Stock (CI) Opinions on Recent Analyst Downgrades Following Q2 Earnings

Precigen COO Rutul Shah sells $219,518 in company stock

Precigen's COO, Rutul R. Shah, sold 33,772 shares of common stock for $219,518 at $6.50 per share on August 3, 2026, while simultaneously acquiring the same number of shares for $78,688 through stock option exercise. Following these transactions, Shah holds 497,751 direct shares and …

Cigna Group (CI) Stock Analysis: Exploring A Potential 23% Upside In The Healthcare Sector

Cigna Group (CI) is presented as an attractive investment in the healthcare sector, offering potential long-term growth and stability. Analysts have given the stock 20 buy ratings and 4 hold ratings, with an average target price suggesting a 23.05% upside. The company demonstrates robust …

PGEN (PGEN) shareholder Rutul Shah files to sell 33,772 common shares

Rutul Shah, a shareholder of Precigen, Inc. (PGEN), has filed a Form 144 to sell 33,772 common shares. The proposed sale, valued at $219,518.00, will occur on or after August 3, 2026, via Fidelity Brokerage Services LLC on NASDAQ. These shares were acquired through …

Cigna Group stock rises Monday, still underperforms market

Cigna Group (CI) stock rose 1.08% on Monday, closing at $282.06, despite the broader market also seeing gains. The stock's performance still lagged behind the S&P 500 Index and the Dow Jones Industrial Average, which rose 1.48% and 1.32% respectively. This increase ended a …

Raymond James cuts Cigna to Outperform on lack of near-term catalysts

Raymond James downgraded Cigna Group (CI) from Strong Buy to Outperform and lowered its price target to $320 from $350, citing a lack of near-term catalysts despite an attractive valuation. The firm noted slower growth in Cigna's mature market and ongoing headwinds in its …

Goldman Sachs Adjusts Price Target on Cigna Group to $352 From $340, Maintain Buy Rating

Goldman Sachs has increased its price target for Cigna Group (CI) to $352 from $340, while reaffirming a Buy rating on the stock. This adjustment reflects an updated outlook from the investment bank regarding the managed healthcare company. The article also notes recent analyst …

Raymond James Adjusts Price Target on Cigna Group to $320 From $350, Maintain Outperform Rating

Raymond James has adjusted its price target for Cigna Group (CI) to $320, down from $350, while maintaining an Outperform rating on the stock. Cigna Group currently holds an average analyst rating of overweight and a mean price target of $342.43. The full details …

Cigna: Specialty Care Profit Jumps 22% As Pharmacy Benefit Earnings Fall 27%

Cigna's second-quarter 2026 earnings showed a significant divergence between its Evernorth Health Services businesses. Specialty and Care Services saw its profit jump 22% due to strong specialty-drug growth and operational efficiencies, while Pharmacy Benefit Services experienced a 27% decline in earnings despite increased revenue, …

Health insurer Cigna boosts full-year earnings guidance after beating Q2 expectations

Cigna has raised its 2026 profit forecast to at least $30.45 per share, an increase of $0.10 from its previous outlook, following strong second-quarter results that surpassed analyst expectations. The improved performance was primarily driven by its Evernorth Health Services division, particularly the Specialty …

Precigen, Inc. Revenue Breakdown – NASDAQ:PGEN

The The Cigna Group (NYSE:CI) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Cigna Group's second-quarter results showed revenues slightly above expectations but EPS slightly below. Analysts have updated their forecasts, but there has been no major change in expectations for the business, with the consensus price target remaining largely unchanged at US$343. Despite a projected slowdown …

Precigen Insider Sold Shares Worth $606,000, According to a Recent SEC Filing

An insider at Precigen, Inc. sold shares valued at $606,000, as reported in a recent SEC filing. This transaction follows other recent insider share sales by the company, including sales worth $1,113,143 and $2,042,864 in early July. Precigen is a biopharmaceutical company focused on …

Cigna (CI) Stock Stalls As Evernorth Carries Growth And PBM Pressure Builds

Cigna's stock experienced a slight dip despite strong Q2 2026 earnings, with adjusted EPS guidance lifted to at least US$30.45. Growth is primarily driven by its Evernorth segment, particularly specialty pharmacy and care services, which are boosting margins. However, concerns remain regarding pressure on …

The Cigna Group Revenue Breakdown – NYSE:CI

Precigen (NASDAQ: PGEN) CFO sells 100,000 shares in 10b5-1 plan

Precigen's Chief Financial Officer, Harry Thomasian Jr., sold 100,000 shares of common stock on July 31, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $6.06, totaling approximately $606,000. Following this transaction, Thomasian Jr. directly holds …

PGEN (PGEN) insider outlines planned sale of 100,000 common shares

Harry Thomasian Jr., an insider at Precigen, Inc. (PGEN), has announced plans to sell 100,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $605,609.66. These shares are related to restricted stock vesting on August 28, 2024. This …

Wells Fargo Adjusts Price Target on Cigna Group to $307 From $305, Maintains Equalweight Rating

Wells Fargo has increased its price target for The Cigna Group (CI) from $305 to $307, while reiterating an Equalweight rating on the stock. This minor adjustment reflects a continued neutral stance on the company's valuation and future performance.